1. You are here:  
  2. Home>
  3. PMCC Staff Publications>
  4. PMCC Staff Publications April 2017

pmcc logo smlHere are the staff publications for February 2017, compiled March 1st.

 

 

Here are the staff publications for February 2017, compiled March 1st.

  1. Alchin DR, Murphy D, Lawrentschuk N. Predicting the risk of positive surgical margins following robotic-assisted radical prostatectomy. Minerva Urologica e Nefrologica 2017;69:56-62.
  2. Bower NI, Vogrin AJ, Le Guen L, et al. Vegfd modulates both angiogenesis and lymphangiogenesis during zebrafish embryonic development. Development 2017;144:507-18.
  3. Buchanan DD, Clendenning M, Rosty C, et al. Tumor testing to identify lynch syndrome in two Australian colorectal cancer cohorts. Journal of Gastroenterology and Hepatology 2017;32:427-38.
  4. Cameron LB, Jiang DH, Moodie K, Mitchell C, Solomon B, Parameswaran BK. Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution. Cancer Imaging 2017;17:7.
  5. Cardoso F, Costa A, Senkus E, et al. 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). Breast 2017;31:244-59.
  6. Chan KL, van der Weyden C, Khoo C, et al. Durable clinical remission induced by romidepsin for chemotherapy-refractory peripheral T-cell lymphoma with central nervous system involvement. Leukemia & Lymphoma 2017;58:996-8.
  7. Chun K, Capitanio JP, Lamkin DM, Sloan EK, Arevalo JM, Cole SW. Social regulation of the lymph node transcriptome in rhesus macaques (Macaca mulatta). Psychoneuroendocrinology 2017;76:107-13.
  8. Dall GV, Vieusseux JL, Korach KS, et al. SCA-1 Labels a Subset of Estrogen-Responsive Bipotential Repopulating Cells within the CD24+ CD49fhi Mammary Stem Cell-Enriched Compartment. Stem Cell Reports 2017;8:417-31.
    Dickinson M, Irving L, Hofman M. Early warning signs: FDG-PET to diagnose bleomycin toxicity. Leukemia & Lymphoma 2017;58:1016-8.
  9. Dimopoulos MA, Trotman J, Tedeschi A, et al. Ibrutinib for patients with rituximab-refractory Waldenstrom's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncology 2017;18:241-50.
    El-Galaly TC, Villa D, Michaelsen TY, et al. The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy. European Journal of Cancer 2017;75:195-203.
  10. Emery JD, Jefford M, King M, et al. ProCare Trial: a phase II randomized controlled trial of shared care for follow-up of men with prostate cancer. BJU International 2017;119:381-9.
  11. Fisher OM, Lord SJ, Falkenback D, Clemons NJ, Eslick GD, Lord RV. The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysis. Gut 2017;66:399-410.
  12. Goldblatt C, Khumra S, Booth J, Urbancic K, Grayson ML, Trubiano JA. Poor reporting and documentation in drug-associated Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis - Lessons for medication safety. British Journal of Clinical Pharmacology 2017;83:224-6.
  13. Grever MR, Abdel-Wahab O, Andritsos LA, et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood 2017;129:553-60.
  14. Hertzberg M, Gandhi MK, Trotman J, et al. Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14. Haematologica 2017;102:356-63.
  15. Imberti C, Terry SY, Cullinane C, et al. Enhancing PET Signal at Target Tissue in Vivo: Dendritic and Multimeric Tris(hydroxypyridinone) Conjugates for Molecular Imaging of alphavbeta3 Integrin Expression with Gallium-68. Bioconjugate Chemistry 2017;28:481-95.
  16. Jung M, Russell AJ, Liu B, et al. A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers. Cancer Research 2017;77:971-81.
  17. Kar SP, Adler E, Tyrer J, et al. Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer 2017;116:524-35.
  18. Kee D, McArthur G. Immunotherapy of melanoma. European Journal of Surgical Oncology 2017;43:594-603.
  19. Kenealy M, Patton N, Filshie R, et al. Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML). Leukemia & Lymphoma 2017;58:298-307.
  20. Kinnane NA, Piper AJ, Jefford M. How will cancer survivors use survivorship care plans? Acta Oncologica 2017;56:183-9.
  21. Kist JW, de Keizer B, Hoekstra OS, Vogel WV. Reply: THYROPET Study: Is It Biology or Technology That Is the Issue? Journal of Nuclear Medicine 2017;58:354-5.
  22. Kong G, Callahan J, Hofman MS, et al. High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging 2017;44:476-89.
  23. Kong JC, Guerra GR, Warrier SK, Ramsay RG, Heriot AG. Outcome and Salvage Surgery Following "Watch and Wait" for Rectal Cancer after Neoadjuvant Therapy: A Systematic Review. Diseases of the Colon and Rectum 2017;60:335-45.
  24. Lamb AD, Zargar H, Murphy DG, Corcoran NM, Hovens CM. Disrupting the Status Quo in Prostate Cancer Diagnosis. European Urology 2017;71:193-4.
  25. Lambertini M, Falcone T, Unger JM, Phillips KA, Del Mastro L, Moore HC. Debated Role of Ovarian Protection With Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Women With Cancer. Journal of Clinical Oncology 2017;35:804-5.
  26. Lieberman L, Barod R, Dalela D, et al. Use of Main Renal Artery Clamping Predominates Over Minimal Clamping Techniques During Robotic Partial Nephrectomy for Complex Tumors. Journal of Endourology 2017;31:149-52.
  27. Luen SJ, Savas P, Fox SB, Salgado R, Loi S. Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. Pathology 2017;49:141-55.
  28. Matheson JA, Te Marvelde L, Mailer S, et al. Prospective evaluation of prognostic indicators for early recurrence of cutaneous melanoma. Melanoma Research 2017;27:43-9.
  29. Murphy DG, Hofman M, Lawrentschuk N, Maurer T. Bringing clarity or confusion? The role of prostate-specific membrane antigen positron-emission/computed tomography for primary staging in prostate cancer. BJU International 2017;119:194-5.
  30. Nolan E, Lindeman GJ, Visvader JE. Out-RANKing BRCA1 in Mutation Carriers. Cancer Research 2017;77:595-600.
    Oates R, Brown A, Tan A, et al. Real-time Image-guided Adaptive-predictive Prostate Radiotherapy using Rectal Diameter as a Predictor of Motion. Clinical Oncology (R Coll Radiol) 2017;29:180-7.
  31. Papa N, Perera M, Hofman MS, Bolton D, Lawrentschuk N. Reply to Fabio Zattoni, Filiberto Zattoni, and Laura Evangelista's Letter to the Editor re: Marlon Perera, Nathan Papa, Daniel Christidis, et al. Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016;70:926-37. European Urology 2017;71:e66-e7.
  32. Pattison DA, Hicks RJ. THYROPET Study: Is It Biology or Technology That Is the Issue? Journal of Nuclear Medicine 2017;58:354.
  33. Phillips C, Jeffree R, Khasraw M. Management of breast cancer brain metastases: A practical review. Breast 2017;31:90-8.
  34. Rebello RJ, Pearson RB, Hannan RD, Furic L. Therapeutic Approaches Targeting MYC-Driven Prostate Cancer. Genes 2017;8.
  35. Rogers TM, Arnau GM, Ryland GL, et al. Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer. Scientific Reports 2017;7:42259.
  36. Ryan J, Akhurst T, Lynch AC, Michael M, Heriot AG. Neoadjuvant 90 Yttrium peptide receptor radionuclide therapy for advanced rectal neuroendocrine tumour: a case report. ANZ Journal of Surgery 2017;87:92-3.
  37. Schiavina R, Novara G, Borghesi M, et al. PADUA and R.E.N.A.L. nephrometry scores correlate with perioperative outcomes of robot-assisted partial nephrectomy: analysis of the Vattikuti Global Quality Initiative in Robotic Urologic Surgery (GQI-RUS) database. BJU International 2017;119:456-63.
  38. Schmiegel W, Scott RJ, Dooley S, et al. Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing. Molecular Oncology 2017;11:208-19.
  39. Seymour JF, Ma S, Brander DM, et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncology 2017;18:230-40.
  40. Shortt J, Ott CJ, Johnstone RW, Bradner JE. A chemical probe toolbox for dissecting the cancer epigenome. Nature Reviews Cancer 2017;17:160-83.
  41. Spicer JA, Miller CK, O'Connor PD, et al. Benzenesulphonamide inhibitors of the cytolytic protein perforin. Bioorganic & Medicinal Chemistry Letters 2017;27:1050-4.
  42. Takeda K, Nakayama M, Hayakawa Y, et al. IFN-gamma is required for cytotoxic T cell-dependent cancer genome immunoediting. Nature Communications 2017;8:14607.
  43. Tam CS, Kimber T, Seymour JF. Ibrutinib monotherapy as effective treatment of central nervous system involvement by chronic lymphocytic leukaemia. British Journal of Haematology 2017;176:829-31.
  44. Teh BW, Harrison SJ, Slavin MA, Worth LJ. Epidemiology of bloodstream infections in patients with myeloma receiving current era therapy. European Journal of Haematology 2017;98:149-53.
  45. Tesson S, Richards I, Porter D, et al. Women's preferences for contralateral prophylactic mastectomy following unilateral breast cancer: What risk-reduction makes it worthwhile? Breast 2017;31:233-40.
  46. Touati N, Tryfonidis K, Caramia F, et al. Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor in breast cancer. European Journal of Cancer 2017;72:95-102.
  47. Vinod SK, Lim K, Bell L, et al. High-risk CTV delineation for cervix brachytherapy: Application of GEC-ESTRO guidelines in Australia and New Zealand. Journal of Medical Imaging and Radiation Oncology 2017;61:133-40.
  48. Ye YH, Seleznev A, Flores HA, Woolfit M, McGraw EA. Gut microbiota in Drosophila melanogaster interacts with Wolbachia but does not contribute to Wolbachia-mediated antiviral protection. Journal of Invertebrate Pathology 2017;143:18-25.
Details